NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update

According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is committed to pioneering transformations in the field of regenerative medicine with new, minimally invasive therapies and we are moving along the regulatory path towards human trials for our first product, ExoPTEN. Our focus remains on enhancing our ExoTherapy platform for the production of nanodrugs, expanding our intellectual property, and forging ...read more